It is not the end of the road for Eli Lilly's product as the FDA requested more data on appropriate doses and safety concerns across treatment arms. Short-term effect is that it now benefits Pfizer's Xeljans which will have the monopoly for treatment of RA. However this does not necessarily guarantee a safe passage for Pfizer as they may also encounter safety and efficacy issues.
We know that MSB's product for RA has no safety issues as per Phase 2 trials results and hence it has a huge advantage over competing treatments. It could well be that MPC treatments is the way to go and this will be a blockbuster if it is ultimately approved for commercialisation.
FDA rejects Lilly RA drug, page-5
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.48 |
Change
0.025(1.72%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.50 | $1.50 | $1.47 | $988.1K | 666.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 44372 | $1.47 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.48 | 52104 | 7 |
View Market Depth
| Last trade - 10.27am 14/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |